Xilio (XLO) Director Robert W. Ross Receives Award

What Happened
Robert W. Ross, a director of Xilio Therapeutics, was granted a derivative award on June 11, 2026 covering 5,000 shares (reported at $0.00 per share, total reported acquisition $0). The filing classifies the transaction as an award/grant of a derivative security (transaction code A) and the attached footnote states the option was granted on June 11, 2026.

Key Details

• Transaction date: June 11, 2026; Form 4 filed June 12, 2026 (appears timely within required reporting window).
• Security: Derivative award (option) for 5,000 shares; reported price $0.00; acquisition amount $0.
• Vesting: Vests 100% on the earlier of (i) June 11, 2027 or (ii) the issuer’s next annual meeting, subject to continued service (per footnote).
• Shares owned after transaction: Not specified in the filing.
• Filing accession: SEC Accession No. 0001193125-26-269397.

Context
This was a grant of a derivative award (an option per the footnote), not an open-market purchase or sale — there was no immediate cash outflow or sale of shares. The eventual economic value to the insider will depend on vesting and any future exercise and the company’s stock price at that time. Director awards are a routine form of compensation; they differ from open-market purchases, which are often viewed as a clearer bullish signal.